GTAEXS617

GTAEXS617 · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GTAEXS617, covering 2026-04-23 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]